Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 30.61 USD 0.43% Market Closed
Market Cap: 437.4m USD

Surmodics Inc
Investor Relations

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Show more
Loading

Earnings Calls

2023 Q4
Feb 2, 2024
Show Transcript
Previous
Next
Stabilizing Interest, Quality, and Expenses
2023 Q4
Feb 2, 2024

The company experienced a $200,000 decline in Q4 interest income due to a decrease in interest-earning assets and lower loan origination activities. Net interest margin is expected to remain stable in the first half and improve in the second half of 2024 as higher-yielding investments mature. Credit quality remains stable, supporting the portfolio's strength, particularly in multifamily and lower-risk commercial real estate. Expense guidance for the next year is projected between $41 million and $42.5 million, with potential savings from a branch sale and reduced legal costs. The company aims to maintain a steady dividend return and targets a 5-8% loan growth, leading to a projected loan-to-deposit ratio of about 90%. As for return on equity, double-digit figures are considered achievable in the future. Efforts to boost fee income are underway, particularly in retail banking and the Trust Department, with an efficiency ratio goal between the low to mid-60s percentage range.

Show Full Analysis

Management

Mr. Gary R. Maharaj
CEO, President & Director
No Bio Available
Mr. Timothy J. Arens
Senior VP of Finance & Information Technology and CFO
No Bio Available
Mr. Gordon S. Weber J.D.
Senior VP of Legal, General Counsel & Secretary
No Bio Available
Mr. Charles W. Olson
Senior VP & President of Medical Device Coatings
No Bio Available
Ms. Teryl L. W. Sides
Senior VP & President of Vascular Interventions
No Bio Available
Mr. John D. Manders
Corporate Controller, VP of Finance & Principal Accounting Officer
No Bio Available
Joel Suiter
Director of Corporate Development
No Bio Available
Mr. Joseph J. Stich
Senior VP of Human Resources & President of In Vitro Diagnostics
No Bio Available

Contacts

Address
MINNESOTA
Eden Prairie
9924 W 74th St
Contacts
+19525007000.0
www.surmodics.com